Contrast-enhanced transrectal ultrasound (CE-TRUS) with cadence-contrast pulse sequence (CPS) technology for the identification of prostate cancer

被引：45

作者：

Seitz, Michael ^{[1
]}

Gratzke, Christian ^{[1
]}

Schlenker, Boris ^{[1
]}

Buchner, Alexander ^{[1
,2
]}

Karl, Alexander ^{[1
]}

Roosen, Alexander ^{[1
]}

Singer, Bernhard B. ^{[3
]}

Bastian, Patrick J. ^{[1
]}

Erguen, Sueleyman ^{[3
]}

Stief, Christian G. ^{[1
]}

Reich, Oliver ^{[1
]}

Tilki, Derya ^{[1
,4
]}

机构：

[1] Hosp Univ Munich, Dept Urol, Munich, Germany

[2] Univ Munich, Laser Lab, LIFE Ctr, Munich, Germany

[3] Univ Hosp Essen, Inst Anat, Essen, Germany

[4] Cornell Univ, Coll Med, Dept Med Genet, Howard Hughes Med Inst, New York, NY USA

来源：

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS | 2011年 / 29卷 / 03期

关键词：

Contrast enhanced ultrasound; Prostate; Prostate cancer; Diagnosis; Transrectal ultrasound; Diagnostic accuracy; Microbubble contrast agent; SECTION PATHOLOGICAL ANALYSIS; REAL-TIME ELASTOGRAPHY; GRAY-SCALE; RADICAL PROSTATECTOMY; DOPPLER SONOGRAPHY; GLEASON SCORE; PSA LEVEL; BIOPSY; ULTRASONOGRAPHY; LOCALIZATION;

D O I：

10.1016/j.urolonc.2009.03.032

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Objectives: Various imaging modalities, such as magnetic resonance imaging (MRI), have been assessed with regard to their value in the detection of prostate cancer (CaP). However, there is a need for less time-consuming and more cost effective procedures in urology. In order to determine the ability of contrast-enhanced transrectal ultrasound (CE-TRUS) to identify CaP, we investigated patients scheduled for radical prostatectomy for CaP and radical cystoprostatectomy for bladder cancer. Material and methods: Between May and August 2008, 35 consecutive patients with CaP and muscle-invasive bladder carcinoma were prospectively enrolled in this single center study. All patients underwent B-mode TRUS and CE-TRUS (Sequoia 512 unit with an endocavity probe EV8C4, 8 MHz; Siemens, Erlangen, Germany) by one investigator blinded to any clinical data before radical surgery. Contrast-enhanced images were obtained after intravenous infusion of a bolus (2.4 ml) of the contrast agent SonoVue (Bracco, Milan, Italy). Ultrasound findings (CE-TRUS and B-mode TRUS) were correlated with step-section histology. Results: On a per-patient basis, sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for detecting CaP with CE-TRUS were 71.0%, 50.0%, 91.7%, and 18.2%, respectively. In comparison with B-mode TRUS (sensitivity 45.2%, specificity 75.0%, PPV 93.3%, and NPV 18.0%), CE-TRUS performed significantly better (P = 0.004, McNemar test). On a per-prostate-lobe basis sensitivity, specificity, PPV, and NPV were 69.0%, 33.3%, 83.3%, and 18.2%. Conclusion: CE-TRUS detected prostate cancer with a modest sensitivity and a high PPV in a selected patient cohort. Future randomized-controlled multicenter studies are needed to further validate the value of CE-TRUS in the detection of CaP. Based on our results, CE-TRUS may not be recommended as a routine procedure in the diagnosis of CaP at present. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：295 / 301

页数：7